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Introduction
High-risk prostate cancer (PCa) accounts for up to 40% of newly 
diagnosed cases and carries a significant risk of progression and 
death (1). There are various definitions for high-risk clinically localized 
PCa; the European Association of Urology (EAU) guidelines use the 
D’Amico risk-group classification to define high-risk PCa as PSA >20 
ng/mL, or Gleason Score (GS) >7, or ≥cT3a (2,3). In the absence of 
high-level evidence, the best management approach for patients 
with high-risk PCa is still under debate. Main treatment options are 
radical prostatectomy (RP) or radiotherapy. It is generally accepted 
that multimodality treatment should be the standard for these 
patients. This usually means surgery followed by radiotherapy (RT) 
or RT with concurrent androgen deprivation therapy (ADT). Even 
though these two primary options have not been compared in a 
randomized prospective trial, RT was usually the favored approach by 
many centers. However, in recent years, favorable outcomes reported 
with RP in high-risk PCa patients have caused increased interest in 
surgery as a part of multimodality treatment (4). A web-based survey 
study exploring the preferences in the management of patients with 
newly diagnosed high-risk PCa among urologists practicing in Europe 
reported that 60% of the urologists preferred RP with extended 
lymphadenectomy (LND) initially as a part of multimodal treatment 
(5). Indeed, the EAU guidelines offers RP as a first step in selected 
patients with a low tumor volume provided that the tumor is not 
fixed to the pelvic wall or that there is no invasion of the urethral 
Yüksek riskli prostat kanseri, PSA >20 ng/mL veya Gleason Score (GS) >7 
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tartışıldıktan sonra karar verilmeli ve multimodal bir tedavi almasının 
gerekebileceği hastaya anlatılmalıdır. Ayrıca, yüksek riskli prostat kanseri 
hastalarında cerrahiye bağlı morbiditeyi makul düzeylerde tutabilmek 
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High-risk prostate cancer (PCa), which is defined as PSA >20 ng/mL 
or Gleason Score (GS) >7 or ≥cT3a, accounts for up to 40% of newly 
diagnosed cases and carries a significant risk of progression and death. 
However, the best management approach for patients with high-risk PCa 
is still under debate. Recently, radical prostatectomy (RP) with extended 
lymphadenectomy (LND) has become popular for the treatment of 
high-risk PCa with good prognosis in selected patients in the context 
of multimodal approach. However, decision should be made after all 
treatments have been discussed by a multidisciplinary team and the 
patient should be informed about the likelihood of a multimodal 
approach. On the other hand, necessity of sufficient surgical expertise 
for RP to keep the level of morbidity acceptable in high-risk PCa patients 
should be kept in mind.
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sphincter, with extended LND due to the fact that estimated risk for 
positive lymph nodes is 15-40% (6). LND should include at least the 
removal of the nodes overlying the external iliac artery and vein, the 
nodes within the obturator fossa located cranially and caudally to 
the obturator nerve, and the nodes medial and lateral to the internal 
iliac artery. With this template, 75% of all anatomical landing sites 
are cleared.
The surgical treatment of clinical stage T3 or locally advanced PCa has 
traditionally been discouraged due to increased risk of positive surgical 
margins (33.5-66%) and lymph node metastases and/or distant 
relapse (7.9-49%) (7,8). Thus, 56-78% of patients primarily treated 
by surgery eventually require adjuvant or salvage RT or ADT (9,10). 
However, RP may provide excellent tumor control in selected patients 
with cT3 disease, with 5-, 10- and 15-year cancer specific survival 
(CSS) ranging between 90% and 99%, 85% and 92% and 62% and 
84%, respectively (1,9,10,11,12). Even in patients with cT4 disease who 
underwent RP, CSS has been found to be 88-92% at 5 years and 92% 
at 10 years (13,14). These survival rates, which are similar to that with 
RT combined with adjuvant ADT, show that RP is superior to RT alone 
(15). Even though more than half of the patients received adjuvant 
ADT and/or RT in most of the presented studies, the high CSS suggests 
that local cancer control by RP remains especially important in men 
with locally advanced disease, since local recurrence after RT carries 
risks of complications, such as urinary obstruction and hematuria 
that have detrimental effects on the patients’ quality of life. Another 
advantage of RP as primary treatment in high-risk PCa is the ability 
for accurate pathologic staging. It has been shown that overstaging 
in cT3 PCa occurs in 13-27% of cases (9,10). Accurate staging guides 
the secondary treatment decisions, thereby help identify patients 
who do need post surgical RT and avoid unnecessary toxicities caused 
by radiotherapy. Additionally, it should be kept in mind that since 
pathologic staging is not always available, a considerable number of 
patients receive unnecessary long-term ADT when treated by primary 
radiotherapy. However, RP for clinical T3-4 cancer requires sufficient 
surgical expertise to keep the level of morbidity acceptable. Increased 
overall surgical experience contributes to decreased operative 
morbidity and improves functional results after RP for clinical T3 
cancer (9,12). It has been shown that continence can be preserved in 
most cases, and in selected cases, potency can also be preserved (13). A 
study comparing the results of RP in patients with localized and T3-4 
PCa did not report any significant difference in surgical morbidity 
except for blood transfusion, operative time, and lymphoceles, which 
showed a higher rate in patients with advanced disease (16).
Patients with high-grade PCa (GS 8-10) and confined to the prostate 
at histopathological examination have a good prognosis after RP. 
Several studies have demonstrated good outcomes after RP in the 
context of a multimodal approach for patients with a biopsy GS >8; 
the CSS rate at 5-, 10- and 15-year follow-up was 96%, 84-88% 
and 66%, respectively (17,1). However, recent studies have reported 
a rate of 31-45% downgrading to GS <7 in the RP specimen in men 
with biopsy GS 8-10 indicating a better biochemically progression 
free survival (BPFS) probability (18,19). Therefore, these patients 
may benefit most from RP as potentially curative resection. It has 
also been reported that health status and age of the patient are also 
important factors influencing prostatectomy outcomes in high-risk 
patients. It has been shown that in very high-risk patients (cT3b/4) 
overall cancer-specific mortality (CSM) rates were low; for healthy 
men, CSM was independent of age, supporting RP even for older 
men and, less healthy group had a higher risk of dying from other 
causes while having low risk of CSM (20). Patients with PSA >20 ng/
mL and clinically organ-confined tumors have good prognosis after 
RP monotherapy with a PSA failure rate of 44-50% at 5 years; a CSS 
rate of 90% and 85% at 10 and 15 years after RP (21,22,23). However, 
these studies demonstrated lowered CSS rates and higher PSA failure 
rates in the presence of concomitant cT3 stage and/or biopsy GS 8-10. 
In a recent study, it has been proven that CSS rate after RP decreases 
as the initial PSA value increases; ten-year CSS rate was 80%, 85% 
and 91% in patients with PSA a level of >100 ng/mL, 50.1-100 ng/
mL and 20.1-50 ng/mL, respectively. However, RP may be an option 
as a part of a multimodal treatment strategy in selected patients with 
PCa since CSS remains relatively high even in those with PSA levels 
>100 ng/mL (24). The role of adjuvant vs. salvage RT is the subject of 
ongoing studies. There are also clinical studies on delivery of RT in the 
neoadjuvant setting for patients with high-risk PCa (25,26).
Traditionally, positive lymph node (LN) status has been considered 
a systemic disease state, thus, positive LN diagnosis during pelvic 
LND has potentially lead to the abandonment of RP in PCa among 
urologists until a retrospective study from Munich comparing the 
results of LN-positive patients with and without RP demonstrated that 
with RP, relative survival of patients at 5 and 10 years was 95% and 
86%, respectively and, without RP, it was 70% and 40%, respectively 
(27). Nevertheless, the combination of RP and early adjuvant ADT 
in LN-positive PCa has been shown to achieve a 10-year CSS rate 
of 60-86% supporting the role of RP as an important component 
of multimodal strategies for LN-positive PCa (27,28,29,30,31,32). 
Additionally, it has been reported that patients with 2 or less positive 
nodes had significantly better CSS at 15-year follow-up compared to 
patients with more than 2 positive nodes (84% vs. 62%) indicating the 
lower incidence of tumor progression in patients with fewer positive 
lymph nodes and in those with microscopic invasion only (33). In 
another study, it was demonstrated that median CSS at 10 years in 
patients with ≤2 or ≥3 positive nodes removed was 78.6% and 33.4%, 
respectively (30). These results make it unclear whether early adjuvant 
ADT should still be used in the present era of increased detection of 
microscopic involvement as a result of more frequently performed 
extended LND. The benefits should be judged against the side effects 
of long-term ADT. Follow-up of PSA and delaying the initiation of 
ADT in patients with rising PSA is therefore an acceptable option in 
selected cases with ≤2 microscopically involved lymph nodes in an 
extended node dissection (6).
Case series have been published on robot-assisted RP in high-risk 
patients with good surgical results. There has been concern about 
extended LND by robotic approach, but it has been suggested that 
with increased expertise, LND can be performed as effective as open 
surgery (34). In the future, the results of ongoing clinical trials on 
issues like the role of LND on oncologic outcomes and survival as 
well as neoadjuvant treatments such as chemotherapy, ADT, and 
radiotherapy, adjuvant vs. salvage RT with or without ADT will provide 
better insight for the role of RP in high-risk PCa patients (25,35,36).
In the context of the literature-based evidence that was presented 
above, the EAU guidelines offers RP with extended LND as a reasonable 
treatment option in selected patients with cT3a PCa, GS 8-10 or PSA 
Kuzgunbay et al. 
Radical Prostatectomy for High-Risk Prostate Cancer
122
Journal of Urological Surgery
2015;3: 120-123
>20 while as an optional treatment in highly selected patients with 
cT3b-4N0 or any N1 PCa in the context of a multimodality approach (6). 
However, management decisions should be made after all treatments 
have been discussed by a multidisciplinary team (including urologists, 
radiation oncologists, medical oncologists and radiologists), and after 
the balance of benefits and side effects of each therapy modality has 
been considered by the patient with regard to their own individual 
circumstances. Patient’s life expectancy and comorbidity should be 
considered. The patient must be informed about the likelihood of a 
multimodal approach. On the other hand, it should be kept in mind 
that sufficient surgical expertise is essential to keep the level of 
morbidity acceptable in high-risk PCa patients.
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